1. Emerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes
   Madhu Khullar et al, 2017, Front. Endocrinol. CrossRef
2. Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification
   Hui Tao et al, 2018, Heart Fail Rev CrossRef
3. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
   Guanghong Jia et al, 2018, Circ Res CrossRef
4. Right ventricular dysfunction and remodeling in diabetic cardiomyopathy
   Yin Kang et al, 2019, American Journal of Physiology-Heart and Circulatory Physiology CrossRef
5. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers
   Perry V. Halushka et al, 2019, Annu. Rev. Pathol. Mech. Dis. CrossRef
6. MiR-451 antagonist protects against cardiac fibrosis in streptozotocin-induced diabetic mouse heart
   Cui Liang et al, 2019, Life Sciences CrossRef
7. Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy
   In-Hwa Park et al, 2019, Diabetes Metab J CrossRef
8. Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals.
   Ioanna Kokkinopoulou et al, 2019, Endocrine CrossRef
9. The impact of epigenetics on cardiovascular disease.
   Dimple Prasher et al, 2020, Biochem Cell Biol CrossRef
10. Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p
    Yongxia Cheng et al, 2020, Exp. Anim. CrossRef
11. miR-410-5p promotes the development of diabetic cardiomyopathy by suppressing PIM1-induced anti-apoptosis
    Xiaofen Xia et al, 2020, Molecular and Cellular Probes CrossRef
12. Epigenetics of Circadian Rhythm Disruption in Cardiovascular Diseases
    Ivana Škrlec, 2020 CrossRef
13. Inhibition of miR‑186‑5p contributes to high glucose‑induced injury in AC16 cardiomyocytes
    Jiamei Jiang et al, 2017, Exp Ther Med CrossRef
14. Current advances in the study of diabetic cardiomyopathy: From clinicopathological features to molecular therapeutics (Review)
    Lin Sun et al, 2019, Mol Med Report CrossRef
15. Isolated downregulation of HCN2 in ventricles of rats with streptozotocin-induced diabetic cardiomyopathy
    Katarina Hadova et al, 2021, BMC Cardiovasc Disord CrossRef
16. Application of Animal Models in Diabetic Cardiomyopathy
    Wang-Soo Lee et al, 2021, Diabetes Metab J CrossRef
17. LncRNA H19 inhibits ER stress induced apoptosis and improves diabetic cardiomyopathy by regulating PI3K/AKT/mTOR axis
    Sixuan Wang et al, 2022, Aging CrossRef
18. Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets
    Misganaw Asmamaw Mengstie et al, 2022, Front. Endocrinol. CrossRef
19. Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality
    Frank Lezoualc’h et al, 2022 CrossRef
20. Effect of Selenium Nanoparticles and/or Bee Venom against STZ-Induced Diabetic Cardiomyopathy and Nephropathy
    Mona M. Lotfy et al, 2023, Metabolites CrossRef
21. Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP
    Ping Fang et al, 2023, DDDT CrossRef